Journal of the Korean Association of Oral and Maxillofacial Surgeons : eISSN 2234-5930 / pISSN 2234-7550

Table. 2.

Table. 2.

Therapeutic dosages of cyclosporine and tacrolimus

Cyclosporine Ref. Tacrolimus Ref.
Oral (Sandimmune and Neoral are not interchangeable)
Sandimmune (Novartis)
• 4 to 12 hours pre-transplant: 14 to 18 mg/kg by mouth for one dose
• Initial single daily dose continued 1-2 weeks post-transplant
• Reduce the dose by 5% per week to maintenance dose of 5 to 10 mg/kg per day by mouth divided twice per day.
Neoral (Novartis)
• 12 hours pre-transplant: 10 to 15 mg/kg in two divided doses by mouth (12 hours apart)
• Initial dosage maintained for 1-2 weeks post-transplant
• Reduce the maintenance dose by 2-6 mg/kg per day in two divided doses by mouth.
IV (maximum concentration 2.5 mg/dL)
• 4 to 12 hours pre-transplant IV: 5 to 6 mg/kg IV for one dose over 2 to 6 hours
• Post-transplant until the patient can tolerate oral therapy: 3 to 5 mg/kg IV once per day.
• Adjust dosage according to trough levels
33,34 Liver transplant: with corticosteroids only
• Oral:
IR: 0.1 to 0.15 mg/kg/day in two divided doses, every 12 hours
ER: Extended release formulation is not FDA approved for liver transplantation due to increased mortality in female liver transplant patients.
• IV: 0.01-0.05 mg/kg as a continuous infusion
Heart transplant: use in combination with azathioprine or MMF
• Oral:
IR: 0.075 mg/kg/day in two divided doses, every 12 hours
• IV: initially 0.01-0.02 mg/kg/day as a continuous infusion
Lung transplant: use in combination with azathioprine or MMF
• Oral:
IR: 0.075 mg/kg/day in two divided doses, every 12 hours
• IV: initial 0.3 mg twice daily (<50 kg) or 0.5 mg (>50 kg) twice daily as a continuous infusion
Kidney transplant: use in combination with azathioprine or MMF
• Oral:
IR: initially, 0.2 mg/kg/day (with azathioprine) or 0.1 mg/kg/day (with mycophenolate mofetil)
XL: 0.15 to 0.2 mg/kg/day with basiliximab induction; 0.2 mg/kg/day without basiliximab induction
XR: initially 0.14 mg/kg/day (with antibody induction)
• IV: 0.03 mg/kg/day as a continuous infusion
35-37
31,38
31,39
31,32,40,41

(IV: intravenous, Ref.: reference, IR: immediate-release, ER: extended-release, FDA: U.S. Food and Drug Administration, MMF: mycophenolate mofetil, XL: extra-long, XR: extended-release)

J Korean Assoc Oral Maxillofac Surg 2023;49:311~323
https://doi.org/10.5125/jkaoms.2023.49.6.311
© JKAOMS